Dialysis Service Provider 'Apex Kidney' raises $ 9 million in Funding round
Apex Kidney Care (AKC), a dialysis service provider, announced on Wednesday that it secured a $9 million Foreign Direct Investment (FDI) from Blue Earth Capital AG for an undisclosed equity stake. The Tata Capital Healthcare Fund (TCHF) portfolio company plans to use the capital to expand high-quality and accessible kidney care services in India.
“With the support of TCHF and BlueEarth, we will continue strengthening our ecosystem for kidney disease patients. Our focus remains on improving accessibility through automation and quality enhancement,” said Dr. Shrirang Bichu, Co-founder of AKC.
He added that the company aims to achieve this by collaborating with clinicians, hospitals, and government entities through Public-Private Partnership (PPP) programs.
AKC, headquartered in Mumbai, was founded in 2008 by renowned nephrologists Dr. Viswanath Billa, Dr. Shrirang Bichu, Dr. Jatin Kothari, and Dr. Rajesh Kumar. The company is led by Director and CEO Indranil Roy Choudhury.
“We are excited to partner with Blue Earth Capital, a key Limited Partner, to co-invest in a TCHF portfolio company. This aligns with our shared vision of making high-quality dialysis care more accessible in India. Co-investments are central to our strategy, providing growth capital and new opportunities for portfolio companies,” said Visalakshi Chandramouli, Managing Partner of Tata Capital Healthcare Fund II.
TCHF had previously invested a similar amount in AKC last year through an equity investment.
Highlighting the significance of the investment, Rohan Ghose, Director of Private Equity Partnerships at BlueEarth, stated that AKC’s focus on semi-urban and rural areas helps bridge a critical gap in healthcare.
“By investing in a mission-driven organization like AKC, we aim to create a meaningful social impact by improving access to life-saving dialysis treatments for underserved populations,” he added.
The partnership between AKC, TCHF, and Blue Earth Capital is expected to drive growth in India’s dialysis sector, ensuring better healthcare access for kidney patients.
“With the support of TCHF and BlueEarth, we will continue strengthening our ecosystem for kidney disease patients. Our focus remains on improving accessibility through automation and quality enhancement,” said Dr. Shrirang Bichu, Co-founder of AKC.
He added that the company aims to achieve this by collaborating with clinicians, hospitals, and government entities through Public-Private Partnership (PPP) programs.
AKC, headquartered in Mumbai, was founded in 2008 by renowned nephrologists Dr. Viswanath Billa, Dr. Shrirang Bichu, Dr. Jatin Kothari, and Dr. Rajesh Kumar. The company is led by Director and CEO Indranil Roy Choudhury.
“We are excited to partner with Blue Earth Capital, a key Limited Partner, to co-invest in a TCHF portfolio company. This aligns with our shared vision of making high-quality dialysis care more accessible in India. Co-investments are central to our strategy, providing growth capital and new opportunities for portfolio companies,” said Visalakshi Chandramouli, Managing Partner of Tata Capital Healthcare Fund II.
TCHF had previously invested a similar amount in AKC last year through an equity investment.
Highlighting the significance of the investment, Rohan Ghose, Director of Private Equity Partnerships at BlueEarth, stated that AKC’s focus on semi-urban and rural areas helps bridge a critical gap in healthcare.
“By investing in a mission-driven organization like AKC, we aim to create a meaningful social impact by improving access to life-saving dialysis treatments for underserved populations,” he added.
The partnership between AKC, TCHF, and Blue Earth Capital is expected to drive growth in India’s dialysis sector, ensuring better healthcare access for kidney patients.
.jpg "Innovating Legal Solutions to Safeguard your Business")
